PreludeDx (United States)

Recent papers from PreludeDx (United States)

1. Validation of a multi-omic biosignature for locoregional recurrence and radiation therapy benefit in breast cancernpj Breast Cancer · 2026
2. Periductal myxoid stroma identifies ductal carcinoma in situ at risk of invasive recurrenceJNCI Journal of the National Cancer Institute · 2026
3. Care coordination solutions for caregivers of transgender, nonbinary, and gender expansive youth: a qualitative study of redacted chat conversationsInternational Journal of Transgender Health · 2026
4. Beyond Fluent Replies: Evaluating Prelude as a Conversation Decision System for Emotionally Loaded Romantic Conversations2026
5. Abstract PS2-08-16: Validation of a multi-omic biosignature to predict locoregional recurrence risk and the benefit of adjuvant radiation therapy in women with early-stage invasive breast cancer treated with breast-conserving surgery and endocrine therapyClinical Cancer Research · 2026
6. Development and cross-validation of a novel multi-omic assay to assess locoregional recurrence risk and adjuvant therapy benefit in early-stage hormone receptor positive invasive breast cancer patientsBreast Cancer Research · 2026
7. Abstract PS5-08-26: The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients with Ductal Carcinoma In SituClinical Cancer Research · 2026
8. PRT3789 is a First-in-Human SMARCA2-Selective Degrader that Induces Synthetic Lethality in SMARCA4-Mutated CancersCancer Research · 2025
9. Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk Ductal Carcinoma In Situ After Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Recurrence RatesInternational Journal of Radiation Oncology*Biology*Physics · 2025
10. A 7-Gene Biosignature for Ductal Carcinoma in situ of the Breast Identifies Subpopulations of HER2-positive Patients With Distinct Recurrence Rates After Breast-Conserving Surgery and Radiation TherapyClinical Breast Cancer · 2024
11. Quantitative comparison of immunohistochemical HER2‐low detection in an interlaboratory studyHistopathology · 2024
12. The Clinical Utility of a 7-Gene Biosignature on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery: An Updated Analysis of the DCISionRT® PREDICT StudyAnnals of Surgical Oncology · 2024
13. Identification of patients with DCIS with low-risk clinicopathology who benefit from radiation therapy with and without endocrine therapy after breast-conserving surgery assessed with the 7-gene biosignature.Journal of Clinical Oncology · 2024
14. Abstract PO4-22-05: Changes in Treatment Recommendation for Patients with Ductal Carcinoma In Situ Using a 7-Gene Predictive Biosignature: Analysis of the PREDICT Australia StudyCancer Research · 2024
15. Abstract PO5-15-11: A Novel Biosignature to Predict Radiation Therapy Response in Early-Stage Invasive Breast Cancer Treated with Breast-Conserving SurgeryCancer Research · 2024
16. In Support of Magnani and TaylorArchives of Pathology & Laboratory Medicine · 2023
17. Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situFrontiers in Oncology · 2023
18. Novel markers in breast pathologyHistopathology · 2022
19. The Story of the Magee Equations: The Ultimate in Applied ImmunohistochemistryApplied immunohistochemistry & molecular morphology · 2022
20. A Novel Biosignature Identifies Patients With DCIS With High Risk of Local Recurrence After Breast Conserving Surgery and Radiation TherapyInternational Journal of Radiation Oncology*Biology*Physics · 2022